ArticleFrontiers in pharmacology2025
Disproportionality analysis of taste disorders using the FDA adverse event reporting system and Japanese adverse drug event report databases.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Severe dysgeusia and weight loss associated with terbinafine use: A case report.Journal of family medicine and primary care · 2026Article
- A hypothesis connecting dysgeusia due to defects in ATP-P2X3 signaling and fatigue in myalgic encephalomyelitis/chronic fatigue syndrome: lessons learned from long-COVID.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Taste disorders, which can diminish the quality of life and potentially affect drug treatment efficacy, are adverse events that may occur with the use of various medications; however, only a few studies have comprehensively examined this relationship. Spontaneous reporting system-based databases, such as the FDA Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER), are efficient sources of information for patients treated with drugs; however, analyses using this type of database have some limitations. To address these gaps in knowledge, we comprehensively analyzed the association between drugs and taste disorders using the FAERS and JADER databases. Methods: The reporting odds ratio (ROR) and Bayesian statistics (Bayesian Confidence Propagation Neural Network, BCPNN) from these databases were used to determine the association between drugs and taste disorders. Weibull distribution and logistic regression were used to investigate the time-to-onset characteristics and odds ratios adjusted for age and sex, respectively, for taste disorders, using data from the FAERS database. Results and discussion: Of the 130 drugs for which a signal was detected in both ROR and BCPNN in the FAERS database, 14 had similar signals in the JADER database. Onset time and logistic regression analyses were performed using the FAERS database to characterize drug-induced taste disorders. The median onset time was the same day of administration for nirmatrelvir/ritonavir and clarithromycin; otherwise, it varied among the other drugs. The hazard for clarithromycin remained constant throughout administration, while the hazards for the other drugs decreased over time. Logistic regression analysis confirmed significant associations between the drugs and taste disorders, even after adjusting for age and sex. Overall, these results indicate that certain drugs may be involved in taste disorders, which, depending on their characteristics, warrants further caution and attention. The findings of this study may help healthcare providers recognize drug-induced taste disorders that can lead to a reduced quality of life and noncompliance with medication.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.